Compare

Enclomiphene vs TB-500

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Enclomiphene

25 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 3% · Mixed 97% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Libido
147

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
75
Nausea
68

Self-reported dose per injection

Median bucket: 2+ mg · Most common: 2+ mg

Reports span 2 to ≥ 2 mg (open-ended top bucket)

2+ mg
147

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 81% said they felt similar to their last entry, 19% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 164 days · Based on 21 repeat reporters

TB-500

103 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 38% · Mixed 62% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
219

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
70
Fatigue
65

Self-reported dose per injection

Median bucket: 2–3 mg · Most common: 2–3 mg

Reports span 0 to ≥ 5 mg (open-ended top bucket)

0–0.01 mg
14
0.025–0.05 mg
1
0.1–0.2 mg
1
0.2–0.4 mg
29
0.4–0.6 mg
25
0.6–1 mg
2
1–2 mg
5
2–3 mg
72
3–5 mg
45
5+ mg
25

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 23% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 63 days · Based on 40 repeat reporters

Sources (10)

Published sources linked on the Enclomiphene and TB-500 wiki pages.

  1. PubMed

    Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement

    Kim ED, McCullough A, Kaminetsky J, et al. BJU Int. 2016

    Source
    Wiki study page →
  2. PubMed

    Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics

    Wiehle R, Cunningham GR, Pitteloud N, et al. BJU international. 2013

    Source
    Wiki study page →
  3. PubMed

    Enclomiphene citrate for the treatment of secondary male hypogonadism

    Rodriguez KM, Pastuszak AW, Lipshultz LI. Expert opinion on pharmacotherapy. 2016

    Source
    Wiki study page →
  4. PubMed

    Thymosin beta 4 and wound healing: a multifunctional peptide

    Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010

    Source
    Wiki study page →
  5. PubMed

    Myocardial regeneration: expanding the repertoire of thymosin β4 in the ischemic heart

    Smart N, Riley PR. Ann N Y Acad Sci. 2012

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    Thymosin beta-4 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  7. PubMed

    Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications

    Goldstein AL, Hannappel E, Sosne G, et al. Expert opinion on biological therapy. 2012

    Source
    Wiki study page →
  8. PubMed

    Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing

    Li X, Zheng L, Peng F, et al. Protein expression and purification. 2007

    Source
    Wiki study page →
  9. PubMed

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026

    Source
    Wiki study page →
  10. PubMed

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

    Rahman OF, Lee SJ, Seeds WA. JAAOS Glob Res Rev. 2026

    Source
    Wiki study page →